The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.
The conversation discusses hair loss treatments for a woman experiencing androgenetic alopecia and seborrheic dermatitis, with suggestions including low-dose oral minoxidil, dutasteride, and hormone replacement therapy. The user is seeking advice due to intolerance to spironolactone and topical minoxidil, and concerns about low testosterone and DHT levels.
Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.
The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.
The conversation discusses finding a source for RU58841 in Australia. Users suggest that while RU58841 is effective, it may harm the scalp, and recommend trying koshine's kx as a safer alternative.
A personalized topical anti-hair loss serum could include high-dose setipiprant, high-dose CB 03-01, low-dose finasteride, minoxidil, latanoprost, and tretinoin. These ingredients are suggested for their potential effectiveness in promoting hair growth.
The user experienced significant hair regrowth in two months using finasteride, topical minoxidil, and weekly microneedling, but developed dark spots on the scalp, possibly from irritation. They plan to try ketoconazole shampoo to address the issue and will consult a dermatologist.
Skepticism about hair loss research motivations, suggesting financial interests hinder finding a cure. Mentions treatments like minoxidil, finasteride, and dutasteride, but notes they are not cures.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
Creatine may increase scalp DHT without affecting serum DHT, potentially speeding up male pattern baldness (MPB) for those genetically prone. Treatments mentioned include Minoxidil, finasteride, and RU58841.
A 43-year-old noticed significant hair thinning and is using topical minoxidil, dermarolling, Alpecin, biotin, zinc, copper, vitamin D, and rosemary oil. They plan to see an endocrinologist and have blood tests scheduled to investigate further.
Some hair loss may be linked to chromosome 20, which isn't affected by DHT blockers like finasteride. Treatments like minoxidil, microneedling, and genetic testing are suggested, but their effectiveness for this type of hair loss is uncertain.
Epibiotech will offer off-the-shelf allogeneic hair multiplication treatment in South Korea, using dermal papilla cells from donors to grow hair in balding areas. This method is cheaper and less invasive than traditional hair transplants.
Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.
Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.
An 18-year-old with diffuse hair thinning is considering switching from a topical Minoxidil 10% + Finasteride 0.1% solution to Minoxidil 5% foam and oral Finasteride 0.5mg, while also addressing vitamin D deficiency and potential scalp inflammation. Users suggest using Nizoral shampoo for inflammation, considering dutasteride for better results, and maintaining vitamin D levels to protect hair follicles from DHT.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
The conversation discusses various hair loss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.
Setipiprant may help with hair maintenance but is not a guaranteed solution for everyone. Other treatments like minoxidil, finasteride, and topical spironolactone are discussed, with varying opinions on their effectiveness.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
A man with thick, white hair is admired for his genetics, leading to discussions about hair loss and the preference for white hair over balding. Some speculate about the use of treatments like finasteride.
A 25-year-old male with DUPA (diffuse thinning including the donor area) has not seen improvement after 14 months on finasteride. He's considering switching to dutasteride (DUT) after advice from a hair loss YouTuber and is also contemplating trying RU58841.
Zinc pyrithione and ketoconazole shampoos may help reduce hair loss by removing DHT from the scalp. Users discuss various treatments, including minoxidil, finasteride, and non-pharmaceutical options like castor oil and dermarolling.
Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.
The user is experiencing asymmetrical hair loss at the frontal hairline and is concerned about potential conditions like frontal fibrosing alopecia. They have started using finasteride and pumpkin seed oil to address the issue.
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
The user is experiencing severe hair loss after surgery and stress, with thinning all over the head, including the sides and neck. They are unsure if it's due to DUPA or alopecia areata incognita, and doctors have not observed miniaturization.
Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.